Optimizing the timing of biologic and surgical therapy for patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP)

Abstract

AbstractIntroductionChronic rhinosinusitis with nasal polyposis (CRSwNP) is often treated with endoscopic sinus surgery (ESS); however, patients may require revision surgery due to recurrence. To date, no studies have compared outcomes for combined surgery and biologic therapy for CRSwNP compared with biologic therapy alone.MethodsRetrospective case–control study of CRSwNP patients who underwent ESS while on dupilumab or mepolizumab (ESS‐biologic cohort) compared with CRSwNP patients on biologic therapy (biologic‐only controls). Cohorts were matched according to indication, aspirin‐exacerbated respiratory disease (AERD), sinonasal outcome test‐22 (SNOT‐22), and total polyp scores.ResultsSixteen patients underwent ESS while on biologic therapy (13 dupilumab and 3 mepolizumab). Sixteen patients were biologic‐only controls. There were no significant differences between indication, baseline SNOT‐22 scores, polyp scores, and AERD status between cohorts. Patients underwent surgery a median of 33 days after starting biologic therapy. After 12 months of follow‐up, the total polyp score for the ESS‐biologic cohort decreased from 4.73 to 0.09 compared with a decrease from 5.22 to 3.38 for the biologic‐only controls (95% confidence interval [CI] of difference: −5.37 to −1.38, Cohen's d: 2.40, p = 0.005). In the ESS‐dupilumab subanalysis, the ESS‐dupilumab cohort had a significant reduction in polyp burden from 4.85 to 0.00 compared with 4.88 to 3.50 for the controls (95% CI of difference: −5.68 to −1.32, Cohen's d: −1.69, p = 0.009).ConclusionIn CRSwNP patients, combined ESS and biologic therapy results in a significant and sustained decrease in polyp burden compared with biologic therapy alone. Larger studies are warranted to further examine the impact of combined therapy.